The VeriStrat test was developed in a different clinical setting, i.e. for prediction of benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC [44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.